FAK inhibitors displayed markedly reduced tumor fibrosis, decreased immunosuppressive MDSCs, and restored unresponsive Kras (G12D)/Trp53 null/Pdx1-cre (KPC) in mouse models of PDAC sensitive to PD-1 blockade [137,138]. This evidence concerns the gene KRAS and neoplasm.